Monday, 16 Sep 2019

PsA/SpA

Datesort ascending Type Title Save
28 Jun 2019 News CAM Use is Common in Psoriasis
24 Jun 2019 Social Study of PsA (N = 341) pts starting secukinumab with or without a baseline loading dose of SEC 150 mg, showed equal ACR20 responses at week 16 - 41.2% vs 39.8%. Despite some w/ an earlier response, the SEC loading dose may not be necessary. https://t.co/d3z9AQoeGM
21 Jun 2019 ACR Video Dr. Christopher Ritchlin - Advances in Psoriatic Arthritis
21 Jun 2019 ACR Video Dr. Atul Deodhar - Treating AS with Secukinumab
17 Jun 2019 Social RT @tuna0sashimi: FUTURE 5 secukinumab in PsA placebo arm only 12w. Week 52 pt can increase doses from 150mg to 300mg. 2y data presented. S…
17 Jun 2019 Social RT @Janetbirdope: EULAR HIGHLIGHTS. Ixekizumab beats adalimumab in PsA on combined end pt of skin + joints due to high skin response #EULAR…
03 Jun 2019 ACR Video RheumNow Live Preview with Dr. Craig Leonardi (Psoriasis Update for Rheumatologists)
03 Jun 2019 News Recommendations for Exercise in Ankylosing Spondylitis
29 May 2019 News Biologic Retention in Ankylosing Spondylitis Patients
29 May 2019 ACR Video RheumNow Live Preview with Dr. John Reveille (Epidemiology & Genetics of SpA)
29 May 2019 Social Metanalysis suggests leflunomide in psoriatic disease is better at treating arthritis (PsA PsARC 77%) than skin disease (psoriasis PASI50 48% & PASI75 25%). Adverse events in 38% and 15% drop out rate. https://t.co/BIPNtYE6Tr
28 May 2019 Social Large UK study shows central adiposity (waist circumference) signify increases risk of psoriasis and rheumatoid arthritis; not PsA. a cross-sectional study of the UK Biobank https://t.co/eKDpUodSR1
17 May 2019 Social Large study from OTIS on PsA and AS shows an increased risk for adverse pregnancy outcomes - including preterm delivery (RR 1.81, 3.82) & Cesarean delivery (RR 1.63, 5.82). Active disease & steroid use may also increase these risks. https://t.co/E10SEq32IO
15 May 2019 Social Danish study of over 13,600 patients with psoriasis finds that after 5 years of follow-up, 2.6% developed psychiatri (depression, anxiety, bipolar disease, schizophrenia and dementia) problems; 5% after 10 years. https://t.co/wssLSxjbSe
13 May 2019 News Low Serious Infection Risk with Newer Agents in Psoriasis
08 May 2019 Social Long term safety of Secukinumab in PsO, PsA, & AS RCTs ( 96,054 patient-years) - favorable results with low incidence of serious infx (1.4, 1.9, 1.2, /100PYs), Candida (2.2, 1.5, 0.7/100pYs), IBD (0.01, 0.05, and 0.1/100PYs) or MACE (0.3, 0.4, 0.6). No TB. https://t.co/BTbBlOYj8W
02 May 2019 Social French real-world study of Psoriatic arthritis pts starting apremilast (n 3207) or MTX (n 2736), finds higher discontinuation rates at 1 yr for apremilast (69%) vs MTX (59%) https://t.co/bhPwaPhX23
29 Apr 2019 ACR Video RheumNow Live Preview with Dr. Elaine Husni (The Changing Paradigm in Spondylitis)
24 Apr 2019 News Skyrizi (risankizumab) FDA Approved for Psoriasis
19 Apr 2019 News Higher Comorbidities in Hidradenitis Suppurativa